Mission statement

Cypralis is focused on the discovery and development of innovative therapeutics for the modulation of peptidyl-prolyl isomerases (known as PPIases), a large family of druggable protein targets known to be involved in many acute and chronic diseases, particularly those where ischaemia, tissue necrosis, fibrosis and tissue remodelling are thought to play a major role.

Please contact us to explore opportunities for collaboration or investment.

+44 (0)1223 496000